Previous Close | 18.47 |
Open | 18.47 |
Bid | 15.60 |
Ask | 19.20 |
Strike | 62.50 |
Expire Date | 2024-05-17 |
Day's Range | 18.47 - 18.47 |
Contract Range | N/A |
Volume | |
Open Interest | 204 |
Recently, Zacks.com users have been paying close attention to Lantheus Holdings (LNTH). This makes it worthwhile to examine what the stock has in store.
Jeffrey S. Humphrey, MD appointed Chief Medical Officer;Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Jeffrey S. Humphrey, MD has been appointed Chief Medical Officer (CMO) and Jean-Claude Provost, MD has been named Chief Sci
Lantheus Holdings (LNTH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.